Drug Shortage Report for OCTREOTIDE FOR INJECTABLE SUSPENSION
Report ID | 166972 |
Drug Identification Number | 02503778 |
Brand name | OCTREOTIDE FOR INJECTABLE SUSPENSION |
Common or Proper name | OCTREOTIDE FOR INJ |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | OCTREOTIDE |
Strength(s) | 20MG |
Dosage form(s) | POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT |
Route of administration | INTRAMUSCULAR |
Packaging size | 1 |
ATC code | H01CB |
ATC description | HYPOTHALAMIC HORMONES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-08-18 |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2024-05-16 |
Company comments | Product under allocation - hospital only |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2022-08-18 | English | Compare |